• The data collected on the entire dose escalation part of study 2019-1001 – a Phase 1 study evaluating NBTXR3 in patients with locally advanced pancreatic adenocarcinoma – show that the use of NBTXR3 activated by radiotherapy is possible and that it is well tolerated.
• The recommended dose for Phase 2 of NBTXR3 activated by radiotherapy in pancreatic cancers is set at 42% of the tumor volume; the dose expansion part is underway in the United States.
• The Company hopes to be able to communicate the data concerning the safety and the first potential signs of efficacy of the escalation part of the study at a medical congress in 2023.